Healthcare
We create and invest in leading companies in therapeutics, medtech, and health IT & services.
33
Thirty three products and drugs approved
With another 12 drugs in phase 3. Typically, only 1 in 5,000 drugs makes it from idea to market.
30+
Over thirty companies created from scratch
If we can't find a company solving an important problem, we create one ourselves - just like we did with Innovent, Denali, Beam and Prime Medicine to name a few.
$3.5B
Over three and a half billion dollars over eleven funds
Without the pressure of fundraising from outside investors, we're privileged to champion companies that help heal the world.
Category
-
GlobeNewswire
Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab
November 18, 2021 -
Owkin
Owkin becomes ‘unicorn’ with $180m investment from Sanofi and four new collaborative projects
November 18, 2021 -
GlobeNewswire
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
November 18, 2021 -
Business Wire
WellAir Launches New Air Cleaning Device That Is 99.9% Effective Against Indoor Airborne Pathogens
November 17, 2021 -
GlobeNewswire
Cytek® Biosciences Marks Milestone Achievement with Shipment of 1000th Cell Analysis System
November 17, 2021 -
GlobeNewswire
BenchSci Named a Deloitte Technology Fast 50™ Company as Impact on Drug Discovery Grows
November 17, 2021 -
GlobeNewswire
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)
November 17, 2021 -
PR Newswire
Embark sponsors The National Dog Show, in commitment to improving life and longevity of all dogs
November 16, 2021 -
PR Newswire
FDA Grants AppliedVR Approval for First Virtual Reality Therapeutic to Treat Chronic Low Back Pain
November 16, 2021 -
PR Newswire
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
November 14, 2021 -
GlobeNewswire
Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer
November 12, 2021 -
PR Newswire
AppliedVR Raises $36 Million Series B To Scale Comprehensive Virtual Reality Platform For Healthcare
November 11, 2021 -
Fierce Healthcare
Former ONC leader Rucker joins interoperability startup 1upHealth
November 10, 2021 -
Reuters
Online medical store PharmEasy targets $842 mln India IPO
November 10, 2021 -
GenomeWeb
Singular Genomics Expands Early-Access Program for New DNA Sequencing Instrument
November 10, 2021 -
GlobeNewswire
Protenus Expands Executive Team With Addition of Experienced Health Tech Leader
November 9, 2021 -
PR Newswire
Centivo launches integrated virtual advanced primary care offering
November 8, 2021 -
PR Newswire
Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
November 7, 2021 -
PR Newswire
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)
November 4, 2021 -
GlobeNewswire
Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting
November 4, 2021 -
TechCrunch
Notable, which makes RPA-based tools to speed up healthcare admin, raises $100M at a $600M valuation
November 3, 2021 -
GlobeNewswire
Cytek Biosciences Acquires Tonbo Biosciences’ Cell Analysis Business
November 3, 2021 -
Business Wire
Gundersen Health System Partners with Kyruus to Propel Digital Access Transformation
November 3, 2021 -
PR Newswire
ABK Biomedical Announces Enrollment Initiation of First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
November 1, 2021 -
Business Wire
Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies
October 28, 2021 -
PR Newswire
Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China
October 27, 2021 -
GlobeNewswire
Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore
October 27, 2021 -
Forbes
Gig Worker Benefits Platform Stride Health Announces $47 Million In New Funding
October 26, 2021 -
Patina Health
Patina Aims to Profoundly Improve the Healthcare and Aging Experience for People 65+ by Reinventing Primary Care; Announces $50 Million Series A Financing
October 26, 2021 -
Business Wire
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
October 21, 2021 -
Business Wire
Xilio Therapeutics Announces Pricing of Initial Public Offering
October 21, 2021 -
FierceHealthcare
One Medical launches new program to target chronic care management market
October 19, 2021 -
PR Newswire
Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer
October 19, 2021 -
Sana
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
October 19, 2021 -
PR Newswire
Prime Medicine Announces Addition of Capabilities to Prime Editing Platform
October 19, 2021 -
Business Wire
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
October 18, 2021 -
Business Wire
Mental Health Leader SonderMind Announces Acquisition of Predictive Analytics Platform Qntfy
October 18, 2021 -
Business Wire
Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
October 18, 2021 -
Business Wire
NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases
October 18, 2021 -
PR Newswire
FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
October 18, 2021 -
PR Newswire
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
October 17, 2021 -
GlobeNewswire
Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay
October 7, 2021 -
GlobeNewswire
GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
October 7, 2021 -
Business Wire
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
October 7, 2021 -
Business Wire
Atalanta Therapeutics Strengthens Leadership Team with Key Appointments in R&D and Corporate Development
October 7, 2021 -
GlobeNewswire
Affinia Therapeutics Appoints Carole Faig to Board of Directors
October 6, 2021 -
GlobeNewswire
Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Scientific Meeting
October 4, 2021 -
PR Newswire
Embark Veterinary Launches First-Ever DNA Test for Purebred Dog Owners
October 4, 2021 -
Business Wire
Firefly Health Launches Health Plan for Employers
October 4, 2021 -
GlobeNewswire
Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring® Treatment for Enlarged Prostate Symptoms
October 4, 2021 -
Business Wire
NOCD Expands OCD Awareness Week Programming to Run Throughout October
October 1, 2021 -
Business Wire
Devoted Health Brings Its Next-Generation Medicare Advantage Plan to Illinois
October 1, 2021 -
Renaissance Capital Report
Solid tumor biotech Xilio Therapeutics files for a $100 million IPO
October 1, 2021 -
PR Newswire
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
September 26, 2021 -
PR Newswire
Behavioral Health Leader Christina Mainelli Joins Quartet Health to Accelerate Strategic Growth
September 23, 2021 -
PR Newswire
Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer
September 23, 2021 -
GlobeNewswire
Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors
September 23, 2021 -
PR Newswire
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
September 23, 2021 -
FierceBiotech
Owkin’s deep learning AI predicts chances of metastatic breast cancer relapse within next 5 years
September 22, 2021 -
PR Newswire
Centivo raises $51 million as more employers seek affordable, quality healthcare for their employees
September 22, 2021 -
Business Wire
NOCD Raises $33 Million to Address Global OCD Crisis; Series B Financing to Support People Struggling with OCD, Fuel Growth
September 21, 2021 -
PR Newswire
Emvitals Partners with SonderMind to make mental healthcare more accessible
September 21, 2021 -
Business Wire
WellAir announces agreement with Vizient, Inc. to help expand air and surface disinfection technologies to healthcare facilities
September 21, 2021 -
GlobeNewswire
Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche
September 20, 2021 -
PR Newswire
Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021
September 17, 2021 -
MobiHealthNews
Indian online pharmacy PharmEasy buys cloud-based hospital supply chain management startup Aknamed
September 16, 2021 -
GlobeNewswire
Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation
September 16, 2021 -
Business Wire
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
September 16, 2021 -
GlobeNewswire
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
September 16, 2021 -
GlobeNewswire
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
September 15, 2021 -
Business Insider India
IPO-bound online pharmacy startup PharmEasy makes its third big acquisition this year
September 15, 2021 -
GlobeNewswire
Owkin Enters Into Agreement to Build Innovative Methods With the Potential to Enhance AI-Enabled External Control Arms
September 15, 2021 -
PR Newswire
Benchling Expands into Early Development Market to Accelerate Delivery of Breakthrough Products
September 14, 2021 -
Business Wire
Kyruus Broadens its Online Scheduling Platform to Allow Consumers to Self-Book Diagnostic and Preventive Care Appointments
September 14, 2021 -
GlobeNewswire
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
September 14, 2021 -
Business Wire
Proximie Selects 8×8 Call and Video Quality Performance Monitoring to Enhance Future of Surgical Healthcare
September 14, 2021 -
GlobeNewswire
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
September 13, 2021 -
PR Newswire
Dr. Patrice Harris Joins Quartet Health’s Board of Directors
September 10, 2021 -
PR Newswire
RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels
September 9, 2021 -
GlobeNewswire
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
September 9, 2021 -
GlobeNewswire
Inovia Capital Partner and Former RIM CFO and COO Dennis Kavelman Joins BenchSci Board of Directors
September 9, 2021 -
PR Newswire
Proximie Partners with Teladoc Health to Connect Operating Rooms Globally
September 9, 2021 -
Business Wire
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
September 9, 2021 -
PR Newswire
Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets
September 8, 2021 -
GlobeNewswire
Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group
September 8, 2021 -
PR Newswire
SoulBeing Joins Buoy Health’s Marketplace to Offer Alternative Medicine Services to Consumers
September 7, 2021 -
PR Newswire
Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation
September 7, 2021 -
PR Newswire
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
September 7, 2021 -
GlobeNewswire
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
September 5, 2021 -
Business Wire
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
September 2, 2021
The list includes investments made by funds managed by F-Prime. The companies are listed in alphabetical order. The list of investments is updated quarterly and, as such, may not reflect most recent F-Prime investments. This list also excludes companies that are currently in stealth.